Dirk Roymans

Dr. Dirk Roymans

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2019 in Science
Verified
Journal Article
Closed access
PDF file
MDMaria J. P. van Dongen
Maria J. P. van Dongen
RKRameshwar U. Kadam
Rameshwar U. Kadam
JJJarek Juraszek
Jarek Juraszek
ELEdward Lawson
Edward Lawson
BBBörries Brandenburg
Börries Brandenburg
IWIan A. Wilson
Ian A. Wilson
A small molecule that targets influenza: Many of us rely on seasonal vaccines for protection against influenza and are only too aware of their limited breadth. Broadly neutralizing antibodies (bnAbs) that target the conserved hemagglutinin (HA) stem of the influenza virus provide hope for the development of universal vaccines and are being evaluated in clinical trials. Van Dongen et al. selected and optimized a small-molecule lead compound that recapitulates key interactions of the bnAb with HA. Like the bnAb, the compound inhibited viral fusion in the endosomes of target cells. The compound protected mice from influenza after oral administration and neutralized virus infection in a 3D cell culture of human bronchial epithelial cells. Science , this issue p. eaar6221

1 August 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
DRDirk Roymans
Dirk Roymans
SASarhad S Alnajjar
Sarhad S Alnajjar
MBMichael B Battles
Michael B Battles
PSPanchan Sitthicharoenchai
Panchan Sitthicharoenchai
PFPolina Furmanova-Hollenstein
Polina Furmanova-Hollenstein
AKAnil Koul
Anil Koul
Respiratory syncytial virus is a major cause of acute lower respiratory tract infection in young children, immunocompromised adults, and the elderly. Intervention with small-molecule antivirals specific for respiratory syncytial virus presents an important therapeutic opportunity, but no such compounds are approved today. Here we report the structure of JNJ-53718678 bound to respiratory syncytial virus fusion (F) protein in its prefusion conformation, and we show that the potent nanomolar activity of JNJ-53718678, as well as the preliminary structure–activity relationship and the pharmaceutical optimization strategy of the series, are consistent with the binding mode of JNJ-53718678 and other respiratory syncytial virus fusion inhibitors. Oral treatment of neonatal lambs with JNJ-53718678, or with an equally active close analog, efficiently inhibits established acute lower respiratory tract infection in the animals, even when treatment is delayed until external signs of respiratory syncytial virus illness have become visible. Together, these data suggest that JNJ-53718678 is a promising candidate for further development as a potential therapeutic in patients at risk to develop respiratory syncytial virus acute lower respiratory tract infection.

29 December 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
DRDirk Roymans
Dirk Roymans
HBHendrik L. De Bondt
Hendrik L. De Bondt
EAEric Arnoult
Eric Arnoult
PGPeggy Geluykens
Peggy Geluykens
TGTom Gevers
Tom Gevers
KAKoen Andries
Koen Andries
Six-helix bundle (6HB) formation is an essential step for many viruses that rely on a class I fusion protein to enter a target cell and initiate replication. Because the binding modes of small molecule inhibitors of 6HB formation are largely unknown, precisely how they disrupt 6HB formation remains unclear, and structure-based design of improved inhibitors is thus seriously hampered. Here we present the high resolution crystal structure of TMC353121, a potent inhibitor of respiratory syncytial virus (RSV), bound at a hydrophobic pocket of the 6HB formed by amino acid residues from both HR1 and HR2 heptad-repeats. Binding of TMC353121 stabilizes the interaction of HR1 and HR2 in an alternate conformation of the 6HB, in which direct binding interactions are formed between TMC353121 and both HR1 and HR2. Rather than completely preventing 6HB formation, our data indicate that TMC353121 inhibits fusion by causing a local disturbance of the natural 6HB conformation.

6 May 2021 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
PSPriscila Sutto-Ortiz
Priscila Sutto-Ortiz
STSergey Tcherniuk
Sergey Tcherniuk
NYNina Ysebaert
Nina Ysebaert
PAPravien Abeywickrema
Pravien Abeywickrema
MNMathieu Noël
Mathieu Noël
EDEtienne Decroly
Etienne Decroly
Respiratory syncytial virus (RSV) is a negative sense single-stranded RNA virus and one of the main causes of severe lower respiratory tract infections in infants and young children. RSV RNA replication/transcription and capping are ensured by the viral Large (L) protein. The L protein contains a polymerase domain associated with a polyribonucleotidyl transferase domain in its N-terminus, and a methyltransferase (MTase) domain followed by the C-terminal domain (CTD) enriched in basic amino acids at its C-terminus. The MTase-CTD of Mononegavirales forms a clamp to accommodate RNA that is subsequently methylated on the cap structure and depending on the virus, on internal positions. These enzymatic activities are essential for efficient viral mRNA translation into proteins, and to prevent the recognition of uncapped viral RNA by innate immunity sensors. In this work, we demonstrated that the MTase-CTD of RSV, as well as the full-length L protein in complex with phosphoprotein (P), catalyzes the N7- and 2’-O-methylation of the cap structure of a short RNA sequence that corresponds to the 5’ end of viral mRNA. Using different experimental systems, we showed that the RSV MTase-CTD methylates the cap structure with a preference for N7-methylation as first reaction. However, we did not observe cap-independent internal methylation, as recently evidenced for the Ebola virus MTase. We also found that at μM concentrations, sinefungin, a S-adenosylmethionine analogue, inhibits the MTase activity of the RSV L protein and of the MTase-CTD domain. Altogether, these results suggest that the RSV MTase domain specifically recognizes viral RNA decorated by a cap structure and catalyzes its methylation, which is required for translation and innate immune system subversion.

13 October 2010 in Future Medicinal Chemistry
Verified
Journal Article
Closed access
DRDirk Roymans
Dirk Roymans
AKAnil Koul
Anil Koul

1 July 2009
Verified
Journal Article
Closed access
JBJean-François Bonfanti
Jean-François Bonfanti
DRDirk Roymans
Dirk Roymans